Potentials of cell kinetics in the management of patients with ovarian cancers

R. Silvestrini, M. G. Daidone, B. Valentinis, E. Di Re, F. Raspagliesi, G. Scarfone, C. Ferraris, G. Bolis, F. Landoni

Research output: Contribution to journalArticlepeer-review


The relevance of 3H-thymidine labeling index (3H-dt LI) on clinical outcome was evaluated on 85 patients with advanced ovarian cancers treated with carboplatin or cisplatin alone (39 cases) or cisplatin in association with doxorubicin and/or cyclophosphamide (46 cases). 3H-dT LI of the primary tumour was significantly related to the 3-year probability of survival in patients treated by monochemotherapy (low LI, 63%; high LI, 21%; P = 0.013) but not in those treated with polychemotherapy. Analysis of the relation between cell kinetics and clinical outcome as a function of treatment showed that in patients with rapidly proliferating tumours the 3-year survival was significantly higher following polychemotherapy than monochemotherapy (51 vs. 21%; P = 0.04). In patients with slowly proliferating tumours no significant difference in survival was observed following the two types of treatment for the overall series, whereas in patients not achieving a complete response survival was significantly higher following monochemotherapy than polychemotherapy (61 vs. 9%; P = 0.008).

Original languageEnglish
Pages (from-to)386-390
Number of pages5
JournalEuropean Journal of Cancer
Issue number2-3
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Potentials of cell kinetics in the management of patients with ovarian cancers'. Together they form a unique fingerprint.

Cite this